<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601871</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG1801</org_study_id>
    <nct_id>NCT03601871</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy</brief_title>
  <official_title>The Efficacy and Safety of Thalidomide in Preventing Multi-cycle, Cisplatin-containing CINV: a Pragmatic Randomized Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yunpeng Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to
      evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced
      delayed nausea and vomiting (CINV) in chemotherapy-naive patients after multi-cycle
      cisplatin-containing highly emetogenic chemotherapy (HEC) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to
      evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced
      delayed nausea and vomiting (CINV) in chemotherapy-naive patients after multi-cycle
      cisplatin-containing highly emetogenic chemotherapy (HEC) . A total of 880 patients are
      planned to be enrolled into the study. Chemotherapy-naïve patients treated with multi-cycle
      cisplatin-containing chemotherapy will be randomized into two groups(thalidomide group and
      control group), and be treated with Thalidomide+5-hydroxytryptamine receptor(5-HT3)
      antagonist +Dexamethasone (Thalidomide group) or 5-HT3 antagonist + Dexamethasone(control
      group), respectively. The primary end point is no nausea rate in delayed phase of the first
      cycle chemotherapy, and the secondary end points include the complete response rate of
      vomiting in acute,delayed and overall period; no nausea rate in acute and overall phase;
      anorexia score, fatigue score and sedation score assessed by VAS ; safety and quality of life
      (QOL) during multi-cycle chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No nausea （self report sclae VAS=0）rate in delayed phase (Days2-7) in the first cycle chemotherapy</measure>
    <time_frame>Day 2-7 in the first chemotherapy cycle(each cycle is 21 days)</time_frame>
    <description>The rate of no nausea on Day 2-7 in the first chemotherapy cycle (each cycle is 21 days).
The no nausea is defined as score zero with a self-report measure scale,the visual analogue (VAS) scale (0,no symptom, 10, most severely).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No nausea rates （VAS=0）for delayed phases (Days2-7) during 2nd to 4th or 6th chemotherapy cycle,respectively.</measure>
    <time_frame>Day 2-7 in each chemotherapy cycle (each cycle is 21 days)</time_frame>
    <description>The rates of no nausea on day 2-7 in 2nd-4th or 6th cycle (each cycle is 21 days).
The no nausea is defined as score zero with a self-report measure scale,the visual analogue (VAS) scale (0,no symptom, 10, most severely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The complete response rates of vomiting (no emetic episode and no rescue) in acute (Day1),delayed(Day2-7), and overall phase(Day 1-7) during 1st to 4th or 6th cycle, respectively.</measure>
    <time_frame>Day 1-7 in 4-6 cycles(each cycle is 21 days)</time_frame>
    <description>The rates of no emetic episode and no rescue in acute(Day1),delayed(Day2-7), and overall phase(Day 1-7) during 1st to 4th or 6th cycle, respectively.(each cycle is 21 days). An emetic episode is defined as one occurrence of vomiting or a sequence of occurrences in close succession not relieved by a rest period of at least 1 min; any number of episodes of retching in a 5-minute period; or an episode of retching of , 5 minutes combined with vomiting not relieved in a 1-minute period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of no anorexia (VAS=0) and score of anorexia (assessed by VAS) in Day1-7 during 1st-4th or 6th cycle chemotherapy</measure>
    <time_frame>Day 1-7 in each cycle(each cycle is 21 days)</time_frame>
    <description>The rate of no anorexia (VAS=0) and score of anorexia assessed by VAS in multi-cycle chemotherapy. Anorexia score is evaluated with VAS (0,no symptom, 10, most severely)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The score of fatigue by VAS in day1-7 in1st to 4th or 6th chemotherapy cycle,respectively.</measure>
    <time_frame>Day 1-7 in each cycle(each cycle is 21 days)</time_frame>
    <description>The score of fatigue by self-report scale VAS in day1-7 in1st to 4th or 6th chemotherapy. fatigue is evaluated with self-report scale VAS (0,no symptom, 10, most severely）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The score of sedation(by self-report VAS) in day 1-7 in each cycle</measure>
    <time_frame>Day 1-7 in each cycle(each cycle is 21 days)</time_frame>
    <description>The score of sedation(by self-report VAS) in day 1-7 in each cycle, respectively.Sedation is evaluated with self-report VAS (0,no symptom, 10, most severely）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 in multi-cycle chemotherapy</measure>
    <time_frame>Day 1-21 in each cycle(each cycle is 21 days) during 4-6 chemotherapy cycles (each cycle is 21 days)</time_frame>
    <description>Number of participants with Treatment-Related Adverse Events as assessed by CTCAE v4.0, in 4-6 cycles (each cycle is 21 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quality of life scores (evaluated with Functional Living Index-Emesis (FLIE) questionnaire) of patients when receiving multi-cycle chemotherapy</measure>
    <time_frame>Day 1-8 in each cycle(each cycle is 21 days) during 4-6 chemotherapy cycles.</time_frame>
    <description>The change of quality of life scores from baseline of patients (before chemotherapy) to D8 after chemotherapy in each cycle (each cycle is 21 days). The quality of life are evaluated with Functional Living Index-Emesis (FLIE) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">880</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thalidomide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .</description>
    <arm_group_label>Thalidomide group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Thalidomide group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-HT3 antagonists</intervention_name>
    <description>Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Thalidomide group</arm_group_label>
    <other_name>Palonosetron, or 1st-generation 5-HT3 antagonists</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18y ≤Age≤70y

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

          -  Histologically confirmed solid neoplasm

          -  No prior chemotherapy

          -  Laboratory test must meet the following criteria: hemoglobin (HGB) ≥90g/ L, neutrophil
             count ≥1.5×109/L, platelet count ≥85×109/L, creatinine clearance rate (CCr) ≥60ml/min,
             total bilirubin (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase
             (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver
             metastasis, the AST/ALT must be ≤5.0 UNL), blood glucose ≤11.1 mmol/L

          -  Life expectancy of at least 12 weeks

          -  Signed informed consent

          -  For women with child bearing potential, a negative serum or urine pregnancy test
             result should be obtained before enrollment;the patients and their couples should
             receive contraception for at least 3 years after their last dosage of thalidomide.

          -  Cancer patients scheduled to receive chemotherapy containing a 50 mg/m2 or higher dose
             of cisplatin for 4-6 cycles

        Exclusion Criteria:

          -  Diabetic patients

          -  Pregnant or lactated women

          -  Patient with history of severe thrombosis

          -  Concomitant radiotherapy

          -  Known hypersensitivity yo thalidomide, palonosetron, or dexamethasone.

          -  Concurrent administration of any other drug which affect antiemetic effect evaluation
             such as proton pump inhibitor, H2 blocker, amifostine, sedative drugs

          -  Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP )regiment or
             taxanes-based regiment

          -  Existing emesis within 24 hours before chemotherapy administration

          -  Symptomatic brain metastasis or suspected clinical brain metastasis

          -  Serious uncontrolled systemic illness or medical condition: congestive heart failure,
             unstable angina, history of documented myocardial infarction within 6 months,
             uncontrolled hypertension and high risk uncontrollable arrhythmias; Obvious
             neurological or mental abnormalities including mental disorder, epileptic dementia,
             which affect compliance; Uncontrolled acute infections; Uncontrolled peptic ulcer or
             other contraindication for corticosteroid therapy.

          -  Inability to take or absorb oral medicine

          -  Concurrent administration of any other investigational drug, or have been enrolled in
             other clinical trial with investigational drug treatment within the 30 days of start
             of study treatment

          -  Unsuitable for the study or other chemotherapy determined by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunpeng Liu, PhD. M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiujuan Qu, PhD. M.D.</last_name>
    <phone>024-83282542</phone>
    <email>qu_xiujuan@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lingyun Zhang, PhD. M.D.</last_name>
    <phone>024-83282312</phone>
    <email>zhangly1105@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>cancer hospital of Haerbin Medical University</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin Wu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siping City Cancer Hospital</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhuohui Qu</last_name>
    </contact>
    <investigator>
      <last_name>Zhuohui Qu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anshan Hospital of First Hospital of China Medical University</name>
      <address>
        <city>Anshan</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingran Sun, PhD.M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Mingran Sun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anshan Tumor Hospital</name>
      <address>
        <city>Anshan</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiuna Zhang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Xiuna Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinfang Lv</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fugang When</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Man</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central hospital of Dalian</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Huo</last_name>
    </contact>
    <investigator>
      <last_name>Wei huo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Zhong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liangwei Yin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhaoxia Dai, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Zhaoxia Dai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Hospital of Dalian City</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jilai Bian</last_name>
    </contact>
    <investigator>
      <last_name>Jilai Bian</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiwei Liu, PhD;M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jiwei Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhuanghe Central Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huali Tang</last_name>
    </contact>
    <investigator>
      <last_name>Huali Tang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fushun Central Hospital</name>
      <address>
        <city>Fushun</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ning</last_name>
    </contact>
    <investigator>
      <last_name>Li Ning</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Mining Bureau</name>
      <address>
        <city>Fushun</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuyang Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Yuyang Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinzhou Central Hospital</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Wang</last_name>
    </contact>
    <investigator>
      <last_name>Wei Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Liaoning Medical University</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhitu Zhu</last_name>
    </contact>
    <investigator>
      <last_name>Zhitu Zhu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese Medicine Hospital of Liaoyang county</name>
      <address>
        <city>Liaoyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haifeng Liu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Haifeng Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoyang Central Hospital</name>
      <address>
        <city>Liaoyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Zhang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jian Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Petrochemical General Hospital of Liaoyang city</name>
      <address>
        <city>Liaoyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao Chen</last_name>
    </contact>
    <investigator>
      <last_name>Hao Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Panjin central Hospital</name>
      <address>
        <city>Panjin</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junwei Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Junwei Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhichang Sun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Jiang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qinghua Gao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chest Hospital of Shenyang City</name>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yinyin Li</last_name>
    </contact>
    <investigator>
      <last_name>Yinyin Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huawei Zou, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Huawei Zou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zhendong Zheng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Tumor Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Tang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yu Tang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunpeng Liu, M.D.;Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yunpeng Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiujuan Qu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lingyun Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>the People'S Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijie He, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Lijie He</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tieling city Central Hospital</name>
      <address>
        <city>Tieling</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huijun Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Huijun Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Anshan City</name>
      <address>
        <city>Anshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuanchun Leng</last_name>
    </contact>
    <investigator>
      <last_name>Chuanchun Leng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benxi Central Hospital</name>
      <address>
        <city>Benxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiejun Chen</last_name>
    </contact>
    <investigator>
      <last_name>Tiejun Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaoyang Central Hospital</name>
      <address>
        <city>Chaoyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiujie Cui</last_name>
    </contact>
    <investigator>
      <last_name>Xiujie Cui</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuening Ji, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Xuening Ji</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gang Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tong Zhao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaohe Oilfield General Hospital</name>
      <address>
        <city>Panjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Chen</last_name>
    </contact>
    <investigator>
      <last_name>Qiang Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 25, 2018</last_update_submitted>
  <last_update_submitted_qc>July 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>Director of Department of Medical Oncology，The First Hospital of China Medical University</investigator_title>
  </responsible_party>
  <keyword>Thalidomide</keyword>
  <keyword>Chemotherapy-induced Nausea and Vomiting</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Serotonin 5-HT3 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

